Shared Strengths: The Merck And Schering Pipelines

Merck’s acquisition of Schering-Plough brings much-needed late-stage assets, including potential blockbusters like TRA and bocepravir; the combined pipelines also strengthens existing footholds in neuroscience and respiratory drugs.

More from Archive

More from Pink Sheet